FDA Rejection Of Narrowed Indication For Daxas Led To Negative Panel Vote

If FDA had accepted Forest's proposed revised indication for Daxas (roflumilast), the chronic obstructive pulmonary disease drug could have yielded a different outcome from the Pulmonary-Allergy Drugs Advisory Committee

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet